Fresenius Kabi

Bortezomib

Manufacturer:

Fresenius Kabi

Bortezomib HCPCS:

J9048

HCPCS Code Descriptor:

Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg

Category:

J Code

Bortezomib NDCs:

63323-0721-10

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Injection

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Bortezomib:

Bortezomib is an Oncology drug manufactured by Fresenius Kabi and administered via the Injection route of administration. The J Code: J9048 is aligned to the drug Bortezomib.

ACCESS PRICING AND MORE BY REGISTERING

J9048 Added Date:

January 1, 2023

J9048 Effective Date:

January 1, 2023

J9048 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Bortezomib billing and coding information.
Bortezomib patient assistance information can be found through KabiCare at the URL: https://kabicare.us/
Bortezomib prescribing information can be found at the link below:
Information regarding Bortezomib’s side effects can be found at MedlinePlus